Intriguing of pharmaceutical product development processes with the help of artificial intelligence and deep/machine learning or artificial neural network

The objectives of current review are (1) to provide a historical overview of artificial intelligence and deep/machine learning (AI & D/ML) or Artificial Neural Network (ANN) (2) to update the financial dealings of pharma companies related to the application of AI & D/ML or ANN in drug discovery and development processes and (3) to showcase the application of AI & D/ML or ANN concept for optimization of analytical method conditions and formula of the dosage form. The optimization of analytical method conditions and formula of dosage form started with the employment of linear model such as design of experiment followed by non-linear model like AI & D/ML or ANN. Such type of linear and non-linear models blending in optimization processes nevertheless helped to suitably identify the influence of critical process parameters or critical material attributes on critical quality attributes. However, much of integration and understandable interpretation between the available data arised from clinical trials and the prevalence/progression of pandemic/endemic infections could potentially be ambitioned through the application of AI & D/ML or ANN.